Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0278080 (
physical dependence
)
1,658
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of a novel kappa-opioid receptor agonist,
TRK
-820, on the development of
physical dependence
on morphine were investigated in mice in comparison with those of U-50,488H. A marked body weight loss and several withdrawal signs were observed following naloxone challenge in morphine-dependent mice. Co-injection of
TRK
-820 (0.003-0.03 mg/kg, s.c.) but not U-50,488H (1-10 mg/kg, s.c.) during chronic morphine treatment dose-dependently suppressed the naloxone-precipitated body weight loss, jumping, wet dog shakes and diarrhea. These results suggest that
TRK
-820-sensitive kappa-opioid receptor subtypes may play a significant role in modulating the development of
physical dependence
on morphine.
...
PMID:A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice. 1089 94
